.Charles Baum, M.D., Ph.D., who oversaw Mirati Therapeutics' $ 5.8 billion sale to Bristol Myers Squibb in 2014, is taking the controls of younger biotech Terremoto Biosciences.Baum's "substantial knowledge in drug growth, and effective record in advancing high-impact medicines, will certainly be instrumental," outgoing CEO Peter Thompson, M.D., mentioned in a July 25 launch. Thompson will retain his seat as board chairperson..Baum, a qualified physician-scientist, was the owner, president and CEO of oncology-focused Mirati. Prior to that, he assisted create cancer drugs at Pfizer as well as Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Currently, Baum is going to act as CEO at Terremoto, a business creating small molecules to target disease-causing proteins-- like those located in harmful lump cells-- using covalent connections. Existing treatments that use covalent connections largely target the amino acid cysteine. However, of the twenty amino acids that compose proteins, cysteine is the least common. Terremoto is actually instead targeting among the essential amino acids, lysine, which is actually located in mostly all proteins.Through targeting amino acid lysine and various other amino acids, Terremoto intends to address recently undruggable conditions and develop first-in-class medications..The biotech, located in South San Francisco, reared $75 million in collection A backing in 2022. A little bit of more than a year eventually, the biotech more than doubled that variety in a $175 million collection B.